A new OHE Consulting Report examines the importance and history of HTA evaluations for additional uses for cancer drugs after their initial approval. The potential value of a new medicine is not likely to be fully known at the time of marketing approval. New uses can expand both the therapeutic and financial value of a particular medicine. In a new study, OHE Consulting seeks to describe and quantify such ‘value expansion’ for a cohort of cancer drugs.
OHE Consulting is now offering our clients advice and analytical services on health outcomes and the use of patient-reported outcomes (PRO) data, building on the extensive programme of original research by OHE in this area. The OHE team is recognised internationally for its methodological work on health outcomes measurement, statistical issues in analysis of PRO data, routine health outcomes data in the NHS, and development of new methods for valuing health states.
In July, OHE released projections for medicines spending in the UK NHS for 2012‒2015. We have now completed further projections, also for the ABPI, for each of the four UK nations (England, Northern Ireland, Scotland and Wales).
Now available from the OHE website, this report provides a clear explanation of the complex nature of innovation in medicines. A fully revised and expanded version of the 2005 edition of The Many Faces of Innovation, it updates the review of the literature on the economics of innovation, traces important innovation that has occurred since the earlier report, adds new case studies, and updates the discussion of competition in pharmaceutical R&D.
At the Spanish Health Economics Association (AES) conference in May 2011, OHE’s Ruth Puig Peiró discussed a recent OHE study that reviewed the available literature on variations in medicines’ efficacy and effectiveness across countries.
Released today is an OHE study commissioned by Cancer Research UK that explores the interdependence between publicly funded and charity funded medical research. In particular, the study focuses on whether and how changes in the levels of government funding affect private funding for charities and, more broadly, medical research and the UK economy as a whole.